Last updated: February 20, 2026
ABSORICA LD is a prescription medication containing isotretinoin, used primarily for severe recalcitrant nodular acne. The drug is produced by companies authorized to license, manufacture, and distribute it under strict regulatory oversight.
Primary Manufacturer and Authorized Suppliers
| Company |
Role |
Location |
Notes |
| Sun Pharmaceutical Industries Ltd. |
Patent holder and primary manufacturer |
India |
Manufactures ABSORICA LD under license from Ortho Dermatologics (a division of Bausch Health). |
| Bausch Health Companies Inc. |
Original marketer and license holder |
United States |
Holds the licensing rights and oversees distribution in the US market. |
| Various authorized generics and regional distributors |
Authorized suppliers in different regions |
Countries worldwide |
These include regional pharmaceutical distributors who supply licensed products under approved distribution channels. |
Licensing and Regulatory Oversight
- License holders: Bausch Health owns the approval and licensing rights for ABSORICA LD in the US.
- Manufacturing agreements: Sun Pharma is licensed to produce ABSORICA LD for global markets, pending regional approvals.
- Regulatory bodies: U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and similar agencies in other regions certify and regulate manufacturing and distribution.
Global Supply Chain Dynamics
- Regional manufacturing: Production occurs mainly in India and North America, aligned with local compliance standards.
- Distribution channels: Authorized pharmacies and specialty distributors hold the license to provide ABSORICA LD, subject to prescription and quality assurance protocols.
- Supply constraints: Periodic shortages can occur due to manufacturing delays, regulatory inspections, or supply chain disruptions.
Alternative Suppliers and Generic Options
- No generic versions of ABSORICA LD are currently authorized in the U.S. as of 2023.
- Certain regional markets may have licensed generics or comparable isotretinoin formulations, but these are not equivalent to ABSORICA LD in branding or specific formulation.
Key Takeaways
- Sun Pharma is the main manufacturing licensee for ABSORICA LD, with Bausch Health providing marketing and distribution rights.
- The drug’s manufacturing is regulated by international agencies, and supply is subject to regional licensing and approvals.
- No generic ABSORICA LD exists in the U.S. as of 2023; distribution is limited to authorized suppliers.
- Regional supply chains vary, with Indian and North American manufacturing facilities primarily involved.
- Supply disruptions, regulatory issues, and licensing restrictions influence availability.
FAQs
Q1. Who holds the manufacturing rights for ABSORICA LD?
Sun Pharmaceutical Industries Ltd. manufactures ABSORICA LD under license from Bausch Health.
Q2. Are there generic equivalents of ABSORICA LD?
No, authorized generics do not exist in the U.S. The formulation is protected under patent rights and licensing agreements.
Q3. How is the drug distributed in the United States?
Distribution occurs through licensed pharmacies and specialty distributors authorized by Bausch Health.
Q4. Which regulatory agencies oversee the manufacturing of ABSORICA LD?
The FDA (U.S.), EMA (Europe), and other regional regulators oversee manufacturing standards and approvals.
Q5. Can regional distributors supply ABSORICA LD globally?
Yes, regional distributors licensed by Bausch Health supply ABSORICA LD in various countries, subject to local regulatory approvals.
References
[1] U.S. Food and Drug Administration. (2022). Abbreviated New Drug Application (ANDA) approvals.
[2] Bausch Health Companies Inc. Official Website. (2023). Product Licensing Information.
[3] Sun Pharmaceutical Industries Ltd. Annual Report. (2022).
[4] European Medicines Agency. (2022). Marketing Authorization Details.
